Dazed By The Cannabis ETF Whirlwind? Here Is A Short Guide To Survival
Cannabis ETFs are experiencing one of their most dynamic years yet, driven by significant regulatory shifts. The Department of Health and Human Services‘ recommendation to reclassify cannabis from a Schedule I to a Schedule III drug under the Controlled Substances Act marks a pivotal moment. This change, coupled with growing Congressional support led by figures like Elizabeth Warren and Chuck Schumer, has invigorated the market.
Investment Trends Amidst Regulatory Shifts
As cannabis transitions from a Schedule I drug, investors are keenly observing the ETFs that are positioned to benefit. According to Jane Edmonds’ article on ETF Trends, the introduction of swap options for U.S. Multi-State Operators (MSOs) has created a unique …